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Abstract
Background: CD147 is an MMP-inducing protein often implicated in cancer progression. The purpose of this study
was to investigate the expression of CD147 in prostate cancer (PCa) progression and the prognostic ability of
CD147 in predicting biochemical recurrence after prostatectomy.
Methods: Plasma membrane-localized CD147 protein expression was quantified in patient samples using
immunohistochemistry and multispectral imaging, and expression was compared to clinico-pathological features
(pathologic stage, Gleason score, tumor volume, preoperative PSA, lymph node status, surgical margins, biochemical
recurrence status). CD147 specificity and expression were confirmed with immunoblotting of prostate cell lines, and
CD147 mRNA expression was evaluated in public expression microarray datasets of patient prostate tumors.
Results: Expression of CD147 protein was significantly decreased in localized tumors (pT2; p = 0.02) and aggressive PCa
(≥pT3; p = 0.004), and metastases (p = 0.001) compared to benign prostatic tissue. Decreased CD147 was associated
with advanced pathologic stage (p = 0.009) and high Gleason score (p = 0.02), and low CD147 expression predicted
biochemical recurrence (HR 0.55; 95 % CI 0.31–0.97; p = 0.04) independent of clinico-pathologic features. Immunoblot
bands were detected at 44 kDa and 66 kDa, representing non-glycosylated and glycosylated forms of CD147 protein,
and CD147 expression was lower in tumorigenic T10 cells than non-tumorigenic BPH-1 cells (p = 0.02). Decreased
CD147 mRNA expression was associated with increased Gleason score and pathologic stage in patient tumors but is
not associated with recurrence status.
Conclusions: Membrane-associated CD147 expression is significantly decreased in PCa compared to non-malignant
prostate tissue and is associated with tumor progression, and low CD147 expression predicts biochemical recurrence
after prostatectomy independent of pathologic stage, Gleason score, lymph node status, surgical margins, and tumor
volume in multivariable analysis.
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Background
An estimated 238,590 new cases of prostate cancer
(PCa) are expected in 2013, accounting for 28 % of total
malignancies in men [1]. After surgery, some patients
experience biochemically recurrent disease, resulting in
unfavorable prognosis and an estimated cancer-specific
mortality of 11–22 % [2]. Treatment options are limited
for patients that progress to metastatic disease, as andro-
gen ablation inevitably leads to lethal castration-resistant
prostate cancer. The identification of prognostic factors
that predict metastatic recurrence after prostatectomy
would allow the stratification of at-risk patients and assist
in more effective individualized treatment. The reliability
of the currently accepted biomarker used to detect PCa
recurrence, prostate-specific antigen (PSA), has recently
been questioned [3], and highlights the urgent need for
more effective PCa-specific biomarkers to guide patient
treatment.
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Matrix metalloproteinases (MMPs) are proteinases
that play a role in tissue remodeling and disease progres-
sion through regulation of the extracellular microenvir-
onment. Extracellular matrix metalloproteinase inducer
CD147 (EMMPRIN, basigin) is a membrane-associated
glycoprotein that stimulates the synthesis of several
MMPs, including interstitial collagenase (MMP-1), gela-
tinase A (MMP-2), stromelysin-1 (MMP-3), and gelati-
nase B (MMP-9) [4–6]. Elevated CD147 expression has
been previously associated with cancer progression and
invasion in malignancies such as breast and colorectal
cancer [7, 8].
Previous studies have observed similar trends in PCa,
with increased CD147 expression in PCa samples com-
pared to matched benign samples and an association with
poor prognosis after prostatectomy [9–13]. However, two
recent studies have reported contrary results, with a de-
crease in CD147 observed with PCa progression [13, 14],
suggesting that CD147 may play a protective role in PCa.
The prognostic role of CD147 in PCa is still debated, as
results thus far are mixed [11–14]. Furthermore, the sensi-
tivity of previous studies has been limited due to semi-
quantitative methods of analyzing immunohistochemical
staining. The purpose of this study was to investigate the
prognostic role of CD147 in PCa and the expression of
CD147 in PCa progression using quantitative multispec-
tral imaging.
Methods
Patient cohort and tissue microarray
The University of Wisconsin Institutional Review Board
(IRB) (M-2007-110-CP003) approved retrospective review
of patient information and demographics and provided
ethical insight to this study in accordance with local and
university policies, state laws, and federal regulations. Pa-
tient consent was not deemed necessary because issues
were obtained from a pathology archive and patient identi-
fying information was anonymized and de-identified prior
to analysis.
The PCa progression tissue microarray (pTMA) and
outcomes tissue microarray (oTMA) were constructed
as previously described [15, 16]. Briefly, all samples were
collected at the University of Wisconsin Hospital from
1985–2005. University of Wisconsin pathologists issued
pathological reports at the time of surgery, and an expert
genitourinary pathologist (WH) extracted pathological
characteristics from the reports retrospectively when
constructing the TMAs. The pTMA includes 384 dupli-
cate cores representing tumor-adjacent normal prostate
(BPT; n = 96 cores), benign prostatic hyperplasia (BPH;
n = 48), high-grade prostatic intraepithelial neoplasia
(HGPIN; n = 50), localized PCa (n = 86), aggressive PCa
(n = 60), and metastases (n = 44). The oTMA includes
462 duplicate cores from normal prostate (n = 96), non-
recurrent PCa (n = 250), and recurrent PCa (n = 116).
Diagnosis for each core was confirmed by a genitourinary
pathologist (WH). Tumor volume values were obtained
from radical prostatectomy reports. Positive margins
were defined as tumor invasion <1mm from the inked
margin. All outcomes patients had ≥5 years of regular
follow-up and no signs of metastatic disease at time of
surgery. Patients included in outcomes analysis had PSA
levels nadir to undetectable levels after prostatectomy,
and recurrence was defined in this analysis as PSA bio-
chemical recurrence above 0.2 ng/ml or local/metastatic
recurrence within follow-up period, as has been previously
published [15, 16].
Immunohistochemistry
Samples were processed and stained by immunohisto-
chemistry (IHC) as previously described [16, 17]. Tissues
were stained using mouse monoclonal anti-CD147 (Me-
ridian Life Science, Memphis, TN; 1:75 in Renoir Red
[Biocare, Concord, CA]), mouse monoclonal anti-E-
caderin (Dako, Carpinteria, CA; 1:200 in Biocare Renoir
Red), and Mach 2 Mouse HRP-Polymer (Biocare) as a
secondary antibody. Bajoran Purple chromogen (Biocare)
was used to detect CD147 and Deep Space Black (Biocare)
was used to detect E-caderin.
Image analysis
Data acquisition and image analysis was performed
using the Vectra slide scanner (PerkinElmer, Waltham,
MA), Nuance software (PerkinElmer) and inForm soft-
ware (PerkinElmer), as previously described [16, 17].
CD147 expression and E-cadherin expression were used
to identify and segment epithelial cell plasma mem-
brane, and hematoxylin was used to segment nuclei
(Additional file 1: Figure S1). CD147 and E-cadherin
expression were then quantified in the membrane and
cytoplasm of the epithelium. Cores with significant
folding or <5 % epithelium were eliminated from ana-
lysis. The average mean OD of duplicate cores was used
for analysis if both cores were available and sufficient
for analysis.
Statistical analysis
Differences in CD147 protein expression were assessed
using the Student’s t-test or one-way ANOVA with
multiplicity adjusted p-values (normal distribution).
Mann-Whitney or Kruskal-Wallis tests were performed
for non-Gaussian distributions. Cox proportional hazards
regression was used to investigate the prognostic ability of
CD147 and E-cadherin, along with clinical and pathologic
variables, including age at surgery, initial pre-surgical
serum PSA, Gleason score, tumor volume, pathologic
stage, lymph node status, and surgical margins. Kaplan-
Meier curves for membranous CD147 and E-cadherin
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expression were constructed based on separation at the
median of expression for PCa patients only, and the log-
rank test was used to compare outcomes in Kaplan-Meier
analysis. A multivariable model was constructed using bio-
marker expression and clinico-pathological variables, and
the assumption of proportional hazards was checked using
Kolmogorov-Smirnov type supremum tests. Because ex-
pression of CD147 was not normally distributed, the me-
dian of CD147 expression was used to divide patients in
multivariable analysis. Using logistic regression, a clinico-
pathological model for predicting 5-year biochemical
recurrence-free survival was created and the area under
the curve (AUC) was calculated. CD147 was then incorpo-
rated into this model and a new AUC was calculated.
MedCalc v11.4 (Ostend, Belgium) was used for statistical
analysis and a two-sided p-value <0.05 was considered sig-
nificant in all analyses.
Publicly available microarray data
Expression of CD147-coding gene BSG mRNA was
assessed using public expression microarray dataset
GSE21034 [18] and GSE25136 [19], available from
National Center for Biotechnology Information Gene
Expression Omnibus [20]. BSG expression data was col-
lected from each dataset, averaged and compared based
on Gleason score, pathologic stage, and recurrence sta-
tus using previously described methods [21].
Immunoblot analysis of PCa progression model cells
In order to investigate the specificity of the CD147
antibody, we used immunoblot analysis of prostate
cell lines. The human non-tumorigenic prostate epi-
thelial cell line BPH-1 and a xenograft-derived BPH1
tumor cell line (T10) were cultured as previously de-
scribed [22, 23]. Cells were solubilized and proteins
were analyzed by immunoblot analysis using mouse
anti-CD147 (Meridian Life Science, Memphis, TN),
and anti-Actin (Santa Cruz Biotechnology, Dallas, TX)
with anti-mouse HRP-conjugated secondary antibodies, as
previously described [24].
Results
Cellular localization of CD147 expression
In preliminary studies, individual sections of a limited
sample of patient PCa tumor tissues were stained for
CD147 and by IHC to optimize staining, visualization,
and quantification of CD147 and E-cadherin. CD147 ex-
pression was primarily detected in the plasma mem-
brane (Fig. 1 and Additional file 1: Figure S1). The
measured expression of membrane-associated CD147
(average mean OD± SD: 0.027 ± 0.011) was 3.3-fold higher
than in the cytoplasm (0.008 ± 0.006; p <0.0001). There-
fore, membrane-associated CD147 was measured and re-
ported. In total, 41 of 384 (10.6 %) of cores in the pTMA
were removed from analysis due to folding or <5 % epithe-
lium, and 18 of 462 (3.9 %) cores were removed from the
oTMA.
Expression of CD147 and E-cadherin in PCa progression
CD147 expression in BPT, BPH, HGPIN, and PCa tumors
was quantified, and all groups were compared to BPT
(Fig. 1). Membrane-associated E-cadherin expression was
significantly decreased in localized PCa (p < 0.0001), ag-
gressive PCa (p < 0.0001), and metastases (p < 0.0001). No
difference was observed between benign prostate tissue
and BPH or HGPIN samples. Membrane-associated
CD147 was significantly decreased in localized PCa
(p = 0.02), aggressive PCa (p = 0.004), and metastases
(p = 0.001). No significant change was observed in
BPH or HGPIN. These results suggest that CD147 ex-
pression is decreased PCa, with lower expression in
advanced tumors and metastases.
Relationship of CD147 expression to tumor pathology
To determine whether decreased CD147 expression
was associated with clinico-pathologic characteristics
and patient outcomes (Table 1), we assessed prostate
cancer specimens using quantitative multispectral im-
aging. CD147 expression was evaluated in relation to
tumor stage. We found that CD147 expression was signifi-
cantly decreased in T3b tumors compared to pT2 tumors
(p = 0.009), but pT3a tumors were not significantly differ-
ent than pT2 (p = 0.77). Decreased CD147 expression also
associated with high Gleason scores (p = 0.02). Addition-
ally, patients experiencing biochemical recurrence within
the follow-up period had significantly lower expression of
CD147 than non-recurrent PCa patients (p = 0.001). There
was no significant relationship between CD147 and tumor
volume, presence of positive surgical margins, or lymph
node status. These results suggest that decreased CD147
expression is associated with some pathologic features of
advanced PCa.
CD147 and post-surgical prognosis
The ability of CD147 and clinico-pathologic characteris-
tics to predict biochemical recurrence after prostatectomy
was assessed in 183 patients on the outcomes TMA
(Table 2). Median follow-up for all patients was 6.2 years
(IQR 5.5-7.4). Lower E-cadherin expression resulted in
poor prognosis after prostatectomy (HR 0.41; CI 0.24–0.68;
p = 0.0007). Patients with lower CD147 expression per-
formed significantly worse (0.61; 0.44–0.82; p = 0.002).
Gleason score (p = 0.005), tumor volume (p = 0.02), patho-
logic stage (p < 0.0001), and lymph node status (p = 0.007)
were significant predictors in univariable analysis. Age at
surgery (p = 0.78), surgical margins (p = 0.07), and initial
serum PSA (p = 0.90) were not predictive of recurrence.
Membrane-associated CD147 and Gleason score were
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predictive of biochemical recurrence in Kaplan-Meier log-
rank analysis (Fig. 2). In bivariable analysis, CD147 ex-
pression was associated with biochemical recurrence
(0.51; 0.29–0.91; p = 0.02) independent of E-cadherin
expression (p = 0.46; data not shown). Lower CD147
expression was predictive of biochemical recurrence
(0.55; 0.31–0.97; p = 0.04) independent of pathologic
stage, Gleason score, lymph node status, and surgical
margins in multivariable analysis (Table 3), and no
variables included in the model violated the propor-
tional hazards assumption (p > 0.05). The AUC for
predicting 5-year biochemical recurrence-free survival
in a model incorporating lymph node status, Gleason
score, and pathologic stage was 0.73. When CD147
staining was incorporated, the AUC increased to 0.76.
CD147 protein in human prostate cell lines
Next, CD147 protein was evaluated in the non-tumorigenic
prostate epithelial cell line BPH-1 and human xenograft-
derived T10 primary metastatic PCa tumor cell line. Bands
were detected at 44 kDa and 66 kDa in both cell lines,
representing non-glycosylated and glycosylated forms of
Fig. 1 Bajoran Purple (BJP) chromogen was used to mark CD147 expression in prostate samples. BJP was separated from the hematoxylin (HT)
counterstain using inForm software (a-f) and was then quantified in the plasma membrane (g). No significant differences were observed between
benign prostatic tissue (BPT; n = 46 patients) and benign prostatic hyperplasia (BPH; n = 23) samples (p = 0.15) or high-grade intraepithelial neoplasia
(HGPIN; n = 24; p = 0.63). Significant decreases in expression were observed in localized prostate cancer (PCa local; n = 42; p = 0.02), aggressive prostate
cancer (PCa aggr.; n = 31; p = 0.004), and metastases (Mets; n = 20; p = 0.001) compared to BPT. E-cadherin was quantified for validation of membrane
segmentation (h), and significant decreases in expression were found in all PCa samples (p < 0.0001) compared to BPT but not in BPH or HGPIN
(p > 0.05) *p < 0.05
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CD147 (Fig. 3a). These results indicate that our antibody is
specific for known isoforms of CD147. After normalizing
to actin, total CD147 expression was significantly de-
creased in tumor-derived T1 (p = 0.02) cells compared to
non-tumorigenic BPH-1 cells (Fig. 3b). Furthermore, both
glycosylated and non-glycoslated CD147 were decreased
in T10 cells compared to BPH-1 cells (p = 0.02 for both).
These data suggest an inverse relationship between
CD147 expression and tumorigenicity in a T + E2-trans-
formed BPH-1 xenograft model.
BSG expression in publicly available microarrays
Expression microarray data from previously published
studies were used to address whether PCa stage- or
recurrence-associated decreases in CD147-encoding
BSG expression are transcriptionally regulated. These
data were originally generated to investigate gene ex-
pression changes in patient prostate tumors in respect
to Gleason Score and tumor stage [18] and PCa recur-
rence [19]. In analysis of PCa samples, decreased BSG ex-
pression was associated with Gleason score ≥8 (p = 0.008)
and pathologic stage pT3b (p = 0.03), but not with post-
surgical recurrence (p = 0.26; Table 4). These results sug-
gest that decreases in CD147 protein expression in
advanced PCa may be transcriptionally regulated.
Discussion
CD147 is a multifunctional glycoprotein that acts to induce
the expression of MMPs, among other roles [4–6, 25].
CD147 also forms heterodimers with proton-coupled
monocarboxylate transporters (MCT) MCT1, MCT3, and
MCT4 [13, 25], helping to maintain lactate and pH homeo-
stasis in epithelial cells, while N-glycosylation of CD147
leads to self-aggregation and MMP induction [26]. Overex-
pression of CD147 of MMPs and CD147 has been noted in
many malignancies, including breast and colorectal cancer
[7, 8], as the mechanistic role of highly glycosylated CD147
is suspected to assist in tumor invasion and metastatic
spread [26, 27]. However, the prognostic role of CD147 is
still controversial, particularly in PCa.
Our results show that CD147 is decreased in malignant
prostate samples compared to tumor-adjacent normal tis-
sue, and further decreases in expression are associated with
Table 2 Univariable analysis of ability to predict disease
recurrence
Hazard Ratio 95 % CI for HR p-value
Age 1.01 0.97–1.04 0.78
Gleason score 0.005
≤6, 3 + 4 ref
4 + 3, ≥8 2.59 1.53–4.40
Tumor volume 0.02
<10 % ref
10–19 % 1.49 0.57–3.90
20–29 % 1.42 0.50–4.03
30–39 % 2.88 1.18–7.05





Positive lymph node(s) 3.58 1.62–7.89 0.007
Initial PSA (per ng/ml) 1.00 0.99–1.01 0.90
Positive surgical margins 1.63 0.96–2.77 0.07




Abbreviations: prostate-specific antigen (PSA), reference (ref), optical
density (OD)
Table 1 Membrane-associated CD147 expression and patient
demographics for PCa outcomes analysis
Number (%) Mean OD (±SD) p-value
Pathologic stage
pT2 143 (78.1) 0.027 (±0.010) -
pT3a 21 (11.5) 0.027 (±0.009) 0.77
pT3b 19 (10.4) 0.021 (±0.007) 0.009
Gleason score
≤6, 3 + 4 143 (78.1) 0.028 (±0.010) -
4 + 3, ≥8 40 (21.9) 0.023 (±0.009) 0.02
Preoperative PSA (ng/ml)
<4 24 (13.1) 0.026 (±0.011) -
4–10 125 (68.3) 0.027 (±0.010) 0.84
>10 34 (18.6) 0.025 (±0.008) 0.87
Tumor volume
<10 % 40 (22.1) 0.026 (±0.011) -
10–19 % 42 (23.2) 0.029 (±0.011) 0.82
20–29 % 29 (16.0) 0.029 (±0.010) 0.27
30–39 % 33 (18.2) 0.026 (±0.009) 0.77
≥40 % 37 (20.4) 0.024 (±0.010) 0.45
Recurrence status
Non-recur 125 (68.3) 0.028 (±0.011) -
Recur 58 (31.7) 0.023 (±0.008) 0.001
Positive margins
No 88 (48.9) 0.027 (±0.010) -
Yes 92 (51.1) 0.026 (±0.010) 0.53
Lymph node status
Negative 169 (95.5) 0.027 (±0.010) -
Positive 8 (4.5) 0.022 (±0.009) 0.15
Abbreviations: prostate cancer (PCa), prostate-specific antigen (PSA), optical
density (OD)
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advanced pathologic stage and Gleason score, indicating
that CD147 may be important in the progression to ad-
vanced stages of PCa. Using a xenograft-derived cell line
model of prostate cancer progression, we confirmed that
CD147 expression was decreased in aggressive PCa. Inves-
tigation of CD147-encoding BSG mRNA expression in
publicly available microarray data shows that CD147 pro-
tein changes may be regulated transcriptionally. In this
study, we also found that CD147 predicts biochemical re-
currence after prostatectomy.
Our results are in disagreement with earlier studies
on the expression and prognostic role of CD147 in
PCa [9–13]. However, one recent study of 11,152 pa-
tients found a decrease in CD147 expression between
PCa and BPT and with increasing stage and Gleason
score [14], and these results are in agreement with one
earlier study on CD147 expression in PCa [13]. How-
ever, these studies concluded that CD147 does not play a
significant prognostic role in determining post-surgical
PSA recurrence [14] or that PCa patients with higher
CD147 expression performed significantly worse [13].
This is the first study, to our knowledge, to demonstrate
that low expression of CD147 is indicative of poor progno-
sis after prostatectomy independent of clinico-pathological
features.
One limitation of previous studies is the semi-
quantitative approach of evaluating immunohistochemical
staining. While these methods are generally effective in
quantitating “on/off” proteins, this approach is less effect-
ive when analyzing proteins with a heterogeneous staining
pattern, particularly when proteins are localized to the
membrane or cytoplasm, as small differences are not read-
ily detected using manual methods of quantification. In
this study, we show that CD147 is primarily localized to
the cellular membrane. Quantitation of E-cadherin in the
membrane portion of the epithelium resulted in a signifi-
cant decrease in expression in all PCa samples compared
to benign prostatic tissue, while HGPIN and BPH samples
showed no significant differences in expression. Further-
more, membrane-associated E-cadherin expression pre-
dicted biochemical recurrence after prostatectomy in
our patient cohort. This data is in agreement with
previous studies on E-cadherin in PCa [16, 28], and
thus validates the epithelial cell membrane segmenta-
tion for investigation of CD147.
Antibodies to N-terminal synthetic peptides or recom-
binant fragments of CD147 have shown predominant
localization to the basal and lateral plasma membrane,
and studies using these antibodies have shown similar
decreases in CD147 expression along PCa progression
[13, 14]. As has been argued previously [14], the use of
different antibodies may account for some of the con-
trasting results found in current literature on CD147.
Some previous studies have shown cytoplasmic and nu-
clear staining of CD147 in PCa specimens [11], rather
than expected membrane-associated localization. Like
previous studies with similar localization and expression
results [13, 14], CD147 protein expression in our cohort
of patient samples was largely present in the plasma
A CB
Fig. 2 Kaplan-Meier estimates of disease recurrence by separation of patients at the median of membrane-associated CD147 expression (a; p < 0.05),
membrane-associated E-cadherin expression (b), and Gleason score (c; p < 0.05)
Table 3 Multivariable analysis of ability to predict disease
recurrence
Hazard Ratio 95 % CI for HR p-value
Gleason score
≤6, 3 + 4 ref
4 + 3, ≥8 1.57 0.89–2.76 0.12
Pathologic stage
T2 ref
T3a 3.46 1.73–6.92 0.0005
T3b 4.12 2.06–8.26 0.0001
Positive lymph node(s) 1.48 0.65–3.40 0.36
Positive surgical margins 1.25 0.70–2.22 0.46
CD147 expression
≤0.025 ref
>0.025 0.55 0.31–0.97 0.04
Abbreviations: reference (ref)
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membrane. Additionally, our immunoblot results showed
bands at molecular weights consistent with both glycosyl-
ated and nonglycosylated forms of CD147. When consid-
ering the known roles and expected localization of CD147
[5, 27], our results suggest high antibody specificity for
known forms of CD147.
Our results differ from previous studies on CD147 and
other malignancies [7, 8]. This may be attributable to the
diverse roles and unusually high amount of post-
translational modifications to CD147. The mechanistic
role of CD147 of inducing MMP expression and pro-
moting extracellular matrix degradation and recon-
struction has implicated CD147 in tumor invasion.
Caveolin-1 is a putative tumor suppressor in other ma-
lignancies [26, 29, 30] that binds CD147 and suppresses
N-glycosylation and CD147-induced fibroblast MMP
activation. Caveolin-1 serves a unique role in PCa, as
secretion and overexpression of caveolin-1 is associated
with advanced disease [31]. Though the interaction of
caveolin-1 and CD147 was not investigated in this
study, the overexpression of caveolin-1 in PCa progres-
sion may serve to bind CD147 and preventing N-
glycosylation, self-aggregation, and MMP induction,
thus accounting for the decrease in CD147 expression
in advanced PCa that we observed.
Furthermore, the N-terminal domain of CD147 is es-
sential for MMP induction [27], as N-glycosylation of
CD147 is associated with self-aggregation and MMP ex-
pression [26]. In HT1080 fibrosarcoma and A431 epi-
dermoid carcinoma cells, purification of a 22-kDa CD147
fragment from culture medium demonstrated cleavage
and shedding of CD147 by membrane-type MMPs in the
linking region between the two Ig-like domains [27]. This
soluble 22-kDa fragment was adequate for augmentation
of MMP-2 expression in human fibroblasts, while the
cleavage of membrane CD147 is expected to downregu-
late the membrane-specific MMP-activating function of
CD147 [27]. N-terminal cleavage and shedding of CD147
has not yet been studied in PCa, but may provide a
mechanistic explanation for the decrease in CD147
with PCa progression that was observed in this and
previous studies [13, 14], as antibodies to the N-
terminal Ig1 domain may not recognize cleaved
forms of CD147. In this study, we also found that
BSG mRNA expression was not significantly associ-
ated with recurrence, indicating that post-translational
modifications of CD147 may be important in the meta-
static spread of PCa. Further studies are needed on post-
translational modified forms of CD147 in PCa to reconcile
the opposing results found throughout the literature.
Limitations of this study include both sample size and
the use of tumor-adjacent normal as a baseline for com-
parison of expression. Compared to previous studies [14]













































Fig. 3 Normalized protein lysates of non-tumorigenic BPH-1 cells and xenograft tumor-derived T10 cells were analysed by Western immunoblot
(a). Actin expression is shown as a control, and error bars represent the standard deviation from three independent experiments. Total CD147
expression was significantly decreased in tumor-derived T1 (p = 0.02) cells compared to non-tumorigenic BPH-1 cells. Similarly, glycosylated
CD147 was significantly reduced in T10 cells (p = 0.02)
Table 4 Evaluation of CD147-encoding BSG expression in PCa
using publically available microarray data
Characteristic Dataset Number Mean (±SD) p-value
Pathologic stage GSE21034
pT2 86 10.17 (±0.34) -
pT3a 30 10.18 (±0.28) 0.88
pT3b,c 17 9.97 (±0.40) 0.03
Gleason score GSE21034
6 77 10.21 (±0.34) -
7 42 10.13 (±0.29) 0.22
≥8 11 9.91 (±0.34) 0.008
Recurrence status GSE21356
Non-recur 40 7.81 (±0.54) -
Recur 39 7.68 (±0.52) 0.26
Abbreviations: prostate cancer (PCa)
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quantitative multispectral platform increases the sensitiv-
ity of our assay and helps to make our sample size suffi-
cient to draw conclusions. The use of tumor-adjacent
normal tissues is common practice due to the difficult
of obtaining truly normal tissues. However, future
studies should incorporate autopsy normal prostate
tissues to avoid the well-documented field effects of
tumors.
Conclusions
Membrane-associated CD147 expression significantly
decreases between benign and malignant prostate sam-
ples but not BPH, and decreases in expression are fur-
ther associated with increasing Gleason score and
pathologic stage, suggesting an association between ad-
vanced PCa and decreased CD147 expression. CD147
staining is predictive of biochemical recurrence after
prostatectomy independent of pathologic stage, surgical
margins, Gleason score, lymph node status, and tumor
volume.
Additional file
Additional file 1: Figure S1. Using inForm software (PerkinElmer), 18 %
of original images (A) were used to create an algorithm of differentiation
to segmental epithelial and stromal components (B). E-cadherin was
used to assist in cellular segmentation (C) of the membrane portion (D).
Expression of CD147 was largely localized to the plasma membrane (E),
as indicated by arrows. (TIFF 18051 kb)
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